

Genomics of Gynaecological Cancer Defining Current and Future Treatment Options

Guest Editors:

Dr. Holly Barker

Cancer Biology and Stem Cells
Division, The Walter and Eliza
Hall Institute of Medical Research
(WEHI), Melbourne, Australia; and
the Department of Medical
Biology, The University of
Melbourne, Melbourne, Australia

Dr. Susana Banerjee

The Royal Marsden NHS
Foundation Trust and Institute of
Cancer Research, London SW3
6JJ, UK

Deadline for manuscript
submissions:

closed (31 October 2022)


Message from the Guest Editors

Next-generation sequencing has enabled individual gynaecological cancers (ovarian, fallopian tube, endometrial (uterine), cervical, vulval or vaginal cancer) to be segregated into different molecular subtypes. Despite molecular differences, subtypes may be treated with the same standard therapies, often with poor responses.

Targeted drugs have been developed for specific molecular alterations and have had a positive impact in the treatment of some types of cancer.

With the increased publication of genomics and pre-clinical precision medicine studies in this area, hopefully, matched clinical trials will prove successful and treatment options for these rare diseases with often poor prognoses will improve. This Special Issue welcomes papers on the genomics of gynaecological cancers (preclinical, clinical and real-world), with a focus on the improvement of the current standard treatments through application of new targeted therapies including immunotherapy based on molecular data.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)